Physician profile
Harold John Wheeler
NPI 1730270786
$2,398.78
in general payments reported to CMS, 2019-2025
28 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $437 · 2021: $455 · 2022: $178 · 2023: $233 · 2024: $270 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $324.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $231.85 | 2019-2021 | |
| Novo Nordisk INC | $222.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $185.02 | 2019-2023 | |
| Lilly USA, LLC | $184.23 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $183.59 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $109.72 | 2019-2021 | |
| Amarin Pharma, INC. | $95.64 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $93.01 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $73.93 | 2019-2021 | |
| Abbvie INC. | $73.56 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $62.36 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $54.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.00 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $51.29 | 2024 | Impella |
| Abbott Laboratories | $49.50 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $43.54 | 2019-2021 | |
| Lundbeck LLC | $40.88 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.68 | 2024 | Caplyta |
| Dexcom, INC. | $30.19 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.64 | 2023 | Nuedexta |
| Grt US Holding, INC. | $20.19 | 2020 | |
| Astellas Pharma US INC | $18.53 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2019 | |
| Indivior INC. | $17.26 | 2019 | |
| Boston Scientific Corporation | $14.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.